March 20, 2026 Release Highlights Copied
Practice Insights announces the implementation of technical fixes within the application to support Merit-Based Incentive Payment System (MIPS) requirements.
MIPS Quality Measures Dashboard
The MIPS Quality Measures Dashboard will be updated to reflect the following:
| Measure | Update | Practice Impact |
| MIPS 450: Appropriate Treatment for Patients with Stage I (T1c) – III HER2 Positive Breast Cancer | This fix will ensure only pathologic staging is assessed for denominator inclusion. Previously, both clinical staging and pathologic staging were assessed for denominator inclusion. | Practices will notice a decrease in denominator and/or numerator. |
Status of Dashboard Updates for 2026
CMS releases updates to the quality measure specifications annually for the MIPS program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. Ontada will continue to notify practices once measures have been updated based on the current 2026 requirements.
The following measures have been fully updated for the 2026 measure year:
| Measure Number | Description |
| MIPS Quality Measures Dashboard | |
| MIPS #001 | Diabetes Hemoglobin A1c (HbA1cc) Poor Control (>9%) (Inverse Measure) |
| MIPS #047 | Advance Care Plan |
| MIPS #143 | Pain Intensity Quantified |
| MIPS #226 | Tobacco Screening and Cessation |
| MIPS #236 | Controlling High Blood Pressure |
| MIPS #238 | Use of High-Risk Medications in Older Adults (Inverse Measure) |
| MIPS #462 | Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy |
| PIMSH #10 | Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs |
| PIMSH #17 | Utilization of Prophylactic GCSF for Cancer Patients Receiving Low-Risk Chemotherapy (Inverse Measure) |